StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright cut their price objective on shares of CASI Pharmaceuticals from $12.00 to $6.00 and set a buy rating on […]